← brief for 2026-09-29 · Slowing decline

Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: an Economic Evaluation.

Article No results yet Peer reviewed

Key takeaways

This study looks at the cost and benefits of a diabetes drug called semaglutide. It estimates how the drug affects society in Canada over five years. It is an economic model, not a clinical trial, so it does not report new medical results.

Who did this work

Husereau D · Evans M · Hahn-Pedersen JH · King R · Kettle J · Bray BD · Berger M · Luckevich M · Lübker C · Mattke S

Source

Article · PubMed, the drug frontier · 2026 Sep 29
https://pubmed.ncbi.nlm.nih.gov/42810438/